TW202108126A - 含有ｃｄ８０胞外域－ｆｃ融合蛋白之醫藥調配物 - Google Patents

含有ｃｄ８０胞外域－ｆｃ融合蛋白之醫藥調配物 Download PDF

Info

Publication number
TW202108126A
TW202108126A TW109114796A TW109114796A TW202108126A TW 202108126 A TW202108126 A TW 202108126A TW 109114796 A TW109114796 A TW 109114796A TW 109114796 A TW109114796 A TW 109114796A TW 202108126 A TW202108126 A TW 202108126A
Authority
TW
Taiwan
Prior art keywords
composition
ecd
concentration
histidine
fusion molecules
Prior art date
Application number
TW109114796A
Other languages
English (en)
Chinese (zh)
Inventor
勇 全
Original Assignee
美商戊瑞治療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商戊瑞治療有限公司 filed Critical 美商戊瑞治療有限公司
Publication of TW202108126A publication Critical patent/TW202108126A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW109114796A 2019-05-03 2020-05-04 含有ｃｄ８０胞外域－ｆｃ融合蛋白之醫藥調配物 TW202108126A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962842722P 2019-05-03 2019-05-03
US62/842,722 2019-05-03

Publications (1)

Publication Number Publication Date
TW202108126A true TW202108126A (zh) 2021-03-01

Family

ID=70847527

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109114796A TW202108126A (zh) 2019-05-03 2020-05-04 含有ｃｄ８０胞外域－ｆｃ融合蛋白之醫藥調配物

Country Status (9)

Country Link
US (1) US20220227834A1 (https=)
EP (1) EP3963079A1 (https=)
JP (1) JP7716988B2 (https=)
AR (1) AR118853A1 (https=)
AU (1) AU2020270395A1 (https=)
CA (1) CA3136831A1 (https=)
MX (1) MX2021013272A (https=)
TW (1) TW202108126A (https=)
WO (1) WO2020227062A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
WO2026062544A1 (en) * 2024-09-23 2026-03-26 Pfizer Inc. Sirp alpha fusion protein formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
US11306144B2 (en) * 2017-08-25 2022-04-19 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof

Also Published As

Publication number Publication date
WO2020227062A1 (en) 2020-11-12
AU2020270395A1 (en) 2021-12-23
EP3963079A1 (en) 2022-03-09
JP2022531387A (ja) 2022-07-06
CA3136831A1 (en) 2020-11-12
AR118853A1 (es) 2021-11-03
MX2021013272A (es) 2021-11-17
JP7716988B2 (ja) 2025-08-01
US20220227834A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
JP7756072B2 (ja) Ｔ細胞調節ポリペプチド及びその使用方法
ES2910969T3 (es) Muteínas de interleucina-21 y métodos de tratamiento
TW202108126A (zh) 含有ｃｄ８０胞外域－ｆｃ融合蛋白之醫藥調配物
TWI820361B (zh) 包含含有il-2蛋白與cd80蛋白之融合蛋白及免疫檢查點抑制劑的用於治療癌症的藥學組成物
JP2024512470A (ja) Ｔ細胞調節ポリペプチド及びその使用方法
CN112771067A (zh) 包含基于SIRPα的嵌合蛋白的组合疗法
US20210246219A1 (en) Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
IL302646A (en) Anti-GDF15 antibody and dosage regimen for cancer treatment
TW202302651A (zh) 一種雙抗組合及其應用
WO2023143547A1 (zh) 抗cd28抗体及其应用
WO2023086929A1 (en) Sirp1a - and cd40l-based chimeric proteins
TW202311293A (zh) 免疫療法之組合及其用途
RU2170589C2 (ru) Композиция для ингибирования ангиогенеза, моноклональное антитело, полипептид, способ ингибирования роста опухоли (варианты)
CN116134053A (zh) 用于使用PD-1 x CTLA-4双特异性分子的方法
US20220111047A1 (en) Formulations of antibodies that bind human cd137 and uses thereof
WO2022212845A2 (en) Pd-1- and ox40l-based chimeric proteins
US20230140384A1 (en) Antibodies to cd40 with enhanced agonist activity
US20220280615A1 (en) Immune tolerant elastin-like recombinant peptides and methods of use
JP2023538902A (ja) 操作されたリガンドを使用する材料及び方法
US20230036928A1 (en) Anti-tgf-beta antibody formulations and their use
RU2828377C1 (ru) Фармацевтическая композиция для лечения злокачественной опухоли, содержащая слитый белок, содержащий белок il-2 и белок cd80, и ингибитор иммунной точки контроля
US20260007744A1 (en) Stable aqueous formulations for antibodies
WO2024173352A2 (en) Methods of treating cancer with a sirp1a-based chimeric protein
CN121693347A (zh) 使用可活化抗ctla4抗体与pembrolizumab组合治疗癌症的方法
TW202523359A (zh) 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合